UNSPSC 51422330: Betamethasone succinate

This classification denotes a therapeutic glucocorticoid with the molecular formula C26H33FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LMR652FZVK. European Medicines Agency schedules betamethasone succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00785MIG. Most nations, for tariff and trade purposes, schedule betamethasone succinate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE SUCCINATE remains US FDA's Preferred Term for this commodity.

SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)CCC(=O)O)O)C)O)F)C.

UNSPSC 51422330 Betamethasone succinate is a Commodity code for a corticosteroid pharmaceutical product, but the recent state and local opportunities tagged to this code do not reflect procurement of the drug itself. Instead, the tagged solicitations address naloxone dispensing systems and direct-to-manufacturer pharmacy benefit programs—neither of which involves betamethasone succinate. The code shows a mismatch between its nominal scope and the work actually being solicited under it in the state and local market. State and local governments that do procure pharmaceutical products, including corticosteroids, typically do so through health departments, county health systems, school districts, and state human services agencies; however, no recent opportunities in the source demonstrate active procurement of betamethasone succinate specifically.

Seminole County, Florida released an IFB for naloxone and drug deactivation systems (due July 26, 2023) focused on community health initiatives, while the Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer pharmacy benefit contracting. Neither opportunity involves the corticosteroid named in this code. The geographic spread of recent activity—Florida and Texas—does not signal concentration; rather, it reflects the mismatch between the code label and current solicitation practice. Because the recent opportunities do not substantively relate to betamethasone succinate procurement, this code presents limited signal for business development professionals pursuing corticosteroid pharmaceutical sales to state and local health agencies. If betamethasone succinate is procured at scale by these jurisdictions, the activity is not reflected in current state and local notice posting under this code.